Blood test may help doctors decide who needs chemo before colon cancer surgery
NCT ID NCT07255729
First seen Jan 04, 2026 · Last updated Jun 23, 2026 · Updated 21 times
Summary
This study is testing whether a blood test that looks at tiny genetic particles called microRNAs can help doctors more accurately stage colon cancer and decide who should get chemotherapy before surgery. Researchers will collect blood samples from 400 colon cancer patients and use machine learning to build a predictive model. If it works, this could lead to a non-invasive way to personalize treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91016, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EXPOSE assay (small RNA-seq) and EXPOSE RT-qPCR panel
What this could lead to
If successful, this could lead to a blood test that helps doctors decide which colon cancer patients need chemotherapy before surgery, potentially improving outcomes.
What could go wrong
This is an early-stage diagnostic study, not a treatment trial. The test may not prove accurate enough in practice, and results may not change patient outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.